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Abstract
Neurodegenerative diseases are characterized by a number of features including the formation of inclusions, early synaptic
degeneration and the selective loss of neurons. Molecules serving as links between these shared features have yet to be
identified. Identifying candidates within the diseased microenvironment will open up novel avenues for therapeutic
intervention. The transcription factor Elk-1 resides within multiple brain areas both in nuclear and extranuclear neuronal
compartments. Interestingly, its de novo expression within a single dendrite initiates neuronal death. Given this novel
regionalized function, we assessed whether extranuclear Elk-1 and/or phospho-Elk-1 (pElk-1) protein might be associated
with a spectrum of human neurodegenerative disease cases including Lewy body Disease (e.g. Parkinson’s), Alzheimer’s
disease, and Huntington’s Disease. We first determined the importance of Elk-1 post-translational modifications on its ability
to initiate regionalized cell death. We next screened human cases from three major neurodegenerative diseases to look for
remarkable levels of Elk-1 and/or pElk-1 protein as well as their association with inclusions characteristic of these diseases.
We compared our findings to age-matched control cases. We find that the ability of Elk-1 to initiate regionalized neuronal
death depends on a specific phosphosite, T417. Furthermore, we find that T417
+ Elk-1 uniquely associates with several types
of inclusions present in cases of human Lewy body Disease, Alzheimer’s disease, and Huntington’s Disease. These results
suggest a molecular link between the presence of inclusions and neuronal loss that is shared across a spectrum of
neurodegenerative disease.
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Introduction
Elk-1 is a member of the ternary complex factor (TCF)
subfamily of ETS-domain transcription factors [1]. It is targeted in
the nucleus by three major MAP kinase pathways as well as the
CaMKII pathway [2]. Phosphorylation of nuclear Elk-1 enhances
its ability to bind DNA at serum response elements and stimulate
transcription of immediate early genes [3]. Within this functional
context, nuclear Elk-1 has been implicated in processes such as
neuronal differentiation [4], cellular proliferation [5] and tumor-
igenesis [6].
There is growing evidence that Elk-1 has broader functional
properties. Expression analysis reveals robust Elk-1 expression
within diverse brain regions including the cortex, hippocampus,
striatum and cerebellum [7]. Subcellular localization analysis
shows Elk-1 mRNA and protein to be present in both nuclear and
extranuclear compartments including the neuronal soma and
dendrites [8]. Furthermore, post-translationally modified forms of
Elk-1 are also present in extranuclear neuronal compartments [8].
This diversity in Elk-1 cellular and subcellular localization implies
diversity in Elk-1 function.
We previously reported the association between Elk-1 and the
mitochondrial permeability transition pore complex (PTP) [9]. The
PTP is a protein complex that forms a functional pore across
mitochondrial membranes. Activation of this pore is believed to
induce both apoptosis and necrosis[10]. In our previous report, co-
IPexperimentsshowthat Elk-1associateswithmultiplecomponents
of the PTP. Electron microscopy of adult rat brain sections show
that this association is present in both neuronal soma and dendrites.
Furthermore,theintroductionofpro-apoptoticstimulienhancesthe
association between Elk-1 and mitochondria in primaryneurons[9].
We previously reported that the de novo synthesis of Elk-1 protein
within a single neuronal dendrite initiates cell death[8]. Here, we
used phototransfection to focally introduce and express small
amounts of mRNA into various compartments of a single primary
hippocampal neuron. Following phototransfection and expression
of Elk-1 mRNA within dendrites, the majority of neurons undergo
cell death that can be seen as early as thirty minutes to several
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Elk-1 translocates from the dendrite into the nucleus as part of the
cell death process. Pharmacological inhibition of transcription
prevents Elk-1 mediated neuronal death. In addition, pharmaco-
logical inhibition of the PTP prevents Elk-1 mediated neuronal
death. These findings describe a unique role for extranuclear Elk-1
protein in regulating neuronal viability through interactions with
the nucleus and mitochondria.
Given that extranuclear Elk-1 has novel functional properties,
we wanted to investigate whether post-translational modifications
could be contributory. Elk-1 contains fifteen sites of post-
translational modification (Figure 1A). The majority of these sites
can be modified in vitro or in vivo [11,12,13,14,15]. However, only a
few sites have been implicated in regulating Elk-1 function and
much of this work has been performed within non-neuronal
systems. Thus, the functional significance of most of these sites is
unknown especially within neuronal systems. For these reasons, we
wanted to determine whether one or more of these sites could be
important in regulating extranuclear Elk-1 function. Specifically,
we tested whether any of these sites were essential for Elk-1 to
mediate neuronal death.
Despite having unique clinical and pathological characteristics,
neurodegenerative diseases are characterized by the abnormal
aggregation of proteins and the formation of inclusions[16,17]. In
addition, the earliest signs of neuronal degeneration are thought to
occur locally in the synapses and the neurites [18]. Furthermore,
they are associated with the selective loss of neurons, though the
mechanism(s) are unknown [16,17]. Given that Elk-1 expresses
within multiple brain areas [7] and its de novo dendritic protein
synthesis leads to neuronal death[8], we wanted to determine
Figure 1. Elk-1 mediated neuronal death is prevented by a specific phosphosite mutation. Elk-1 protein contains fifteen sites of post-
translational modification (Panel A). Phototransfection introduces small amounts of mRNA into various compartments of a single primary
hippocampal neuron allowing for localized protein expression (Panel B). Primary hippocampal neurons were phototransfected within a neuronal
dendrite under mock conditions (Panel D, n=90), with Elk-1 mRNA (Panel F, n=105), T417A Elk-1 mRNA (Panel H, n=80) and S383A Elk-1 mRNA
(Panel J, n=49). Cell death was determined based on cellular morphology (Panel E, G, I, K). White dots represent the regions targeted for
phototransfection. A graph compares % cell viability following phototransfection with the different mRNAs (Panel C). (error bars = SEM, *P,0.05).
doi:10.1371/journal.pone.0009002.g001
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involved in neuronal death associated with neurodegenerative
disease. We tested for remarkable Elk-1 and/or pElk-1 protein in
the classic brain regions undergoing clinically significant neuronal
loss in either human Lewy Body disease (e.g. Parkinson’s Disease),
Alzheimer’s disease (AD), or Huntington’s Disease (HD). Specif-
ically, we tested for an association between Elk-1 and/or pElk-1
protein with inclusions present in these diseases, the areas that
indicate disease pathogenesis.
Results
Elk-1 Neuronal Death Is Phosphosite-Dependent
We first assessed whether Elk-1 mediated neuronal death
depends on one or more sites of post-translational modification.
Since phototransfection introduces only a small amount of Elk-1
mRNA into a single dendrite of primary neurons, the phosphor-
ylation status of de novo synthesized Elk-1 cannot be detected.
Consequently, mutational and functional analysis was utilized to
determine the importance of these sites on de novo synthesized Elk-1.
Here, site-directed mutagenesis created Elk-1 mRNA mutated at a
single site. Then, each mutant mRNA was separately phototrans-
fected into neuronal dendrites to determine its effects on cell
viability in comparison to wildtype Elk-1 mRNA and a mock
phototransfection without mRNA (Figure 1B). Our preliminary
screen showed that the majority of mutant mRNAs were able to
recapitulate wildtype Elk-1 mediated cell death suggesting that their
respective siteswerenotessentialinthe celldeathprocess.However,
select mutant mRNAs were not effective in initiating neuronal
death. We selected one mutant mRNA from each group for a more
thorough analysis including S383A Elk-1 (caused cell death to a
similar extent as native Elk-1) and T417A Elk-1 (the mutant, that in
the initial screening, most consistently did not cause cell death).
Primary hippocampal neurons were phototransfected within single
dendrites with either wildtype Elk-1 mRNA or one of the two
mutant mRNAs. Cell viability was determined based on morphol-
ogy within six hours of phototransfection (Figure 1C). Following
phototransfection of wildtype Elk-1 mRNA, the majority of neurons
undergo cell death within hours that is characterized by dendritic
fragmentation and somatic swelling (Figures 1F–G). Phototransfec-
tionofS383AElk-1mRNAinitiatescelldeathwithsimilartemporal
and morphological characteristics in a majority of neurons
(Figure 1J–K). Differences in percent cell viability following
phototransfection of S383A Elk-1 mRNA compared to photo-
transfection with wildtype Elk-1 mRNA were not statistically
significant (Figure 1C). In contrast, following phototransfection of
T417A Elk-1 mRNA, the majority of neurons do not show a cell
death phenotype within six hours (Figure 1H–I), similar to mock
phototransfection (Figure 1C). These experiments demonstrate that
Elk-1 mediated neuronal death is prevented by a specific
phosphosite mutation at T417. They suggest that T417
+ Elk-1
protein is essential in mediating neuronal death.
We next assessed whether there could be an association between
Elk-1 and/or pElk-1 protein with inclusions present in neurodegen-
erative disease. Here, cases were selected based upon their final
postmortem diagnosis, which was either a variant of Lewy Body
Disease (e.g. Parkinson’s Disease), Alzheimer’s Disease or Hunting-
ton’s disease. Postmortem brain tissue from age-matched control
patientswasalsoincludedforcomparison.TableS1includesrelevant
disease characteristics about the patients selected for this study.
Elk-1 and Lewy Body Disease
We first tested whether Elk-1 protein can co-localize with Lewy
bodies in brain tissue from patients with Lewy Body Disease. A
cohort of cases representing a spectrum of Lewy Body Disease with
a wide range in pathology was selected for this analysis. The cases
exhibit a wide range in the number of neurons containing Lewy
bodies as well as the severity of neuronal loss (Table S2). The cases
examined here include patients with subcortical predominant
Lewy bodies (i.e. classical Parkinson’s Disease), patients with
neocortical involvement (i.e. Diffuse Lewy Body Disease, Lewy
Body Disease with Dementia) as well as patients with a preclinical
presentation of Lewy Bodies (Methods S1). Figure 2A–C contains
representative images demonstrating co-localization of Elk-1 with
a Lewy body in tissue from a patient with Lewy Body Disease.
Using a stringent staining paradigm, serially adjacent 7 mm
sections containing substantia nigra were processed with H&E
(Figure 2A), an antibody against total Elk-1 (Figures 2B), and an
antibody against alpha-synuclein (Figure 2C). Arrows demonstrate
that a classic Lewy body in a neuromelanin-containing neuron
(arrow in Figure 2A) also contains Elk-1 (arrow in Figure 2B) and
alpha-synuclein (arrow in Figure 2C). Elk-1 immunoreactivity,
assessed in the middle adjacent section, localizes to the central core
region of the Lewy body and not the halo. A nearby blood vessel is
used for cross-sectional XY alignment. Elk-1 signal is present in
each of the Lewy bodies imaged in Figure 2. This is apparent by
comparing the signals from Figure 2 with those Lewy bodies
lacking signal in Figure S1. Overall, a subset of Lewy bodies show
Elk-1 co-localization. Here, the level of staining and the degree of
Lewy body co-localization can depend on a number of detection
and disease variables [19,20]. Despite using a conservative staining
paradigm, multiple examples of co-localization were identified,
including from each Lewy Body Disease variant listed in Table S1.
We next tested whether any phosphoforms of Elk-1 were
present in these inclusions. Here, we used an antibody against
S383
+ Elk-1, a phosphoform studied within the context of nuclear
Elk-1 function. We also used an antibody against T417
+ Elk-1, a
phosphoform identified as likely being essential for regionalized
neuronal death. Finally, we used an antibody against T368
+ Elk-1,
a phosphoform of unknown functional relevance.
Figure 2D–E includes representative images demonstrating that
T417
+ Elk-1 inclusions display classic Lewy body morphologies in
tissue from a patient with Lewy Body Disease (LBD). T417
+ Elk-1
immunoreactivity stains the core region of multiple intracellular
inclusions in a neuromelanin-containing neuron (arrows in
Figure 2D). When overlaid with H&E, the inclusions exhibit
classical dark pink eosinophilic centers surrounded by lighter pink
halos characteristic of Lewy bodies (arrows in Figure 2E). The co-
localization of T417
+ Elk-1 with Lewy bodies is present in tissue
from other variants of Lewy Body Disease. However, similar
experiments utilizing antibodies specific for S383
+ Elk-1 and
T368
+ Elk-1 do not show co-localization with Lewy bodies (Figure
S1 A/B). Substantia nigra tissue from age-matched control
patients does not contain T417
+ Elk-1 inclusions. Occasional
neurons do exhibit significant immunostaining for T417
+ Elk-1
(Figure S2 A/B, arrow). Interestingly, strong nuclear T417
+ Elk-1
immunoreactivity is identified within substantia nigral glial cells
(Figure 2B).
Pale bodies are thought to be precursors of Lewy bodies and
have been shown to share a subset of antigenic determinants[21].
Figure 2F-I shows that within a group of substantia nigra neurons
from a patient with a preclinical presentation of LBD, a subset of
neurons contains pale bodies (Figure 2F; arrows). These
intracytoplasmic inclusions are characterized by their larger size,
light glassy eosinophilic character and absence of halos. Of the
three neurons containing pale bodies, two show increased Elk-1
expression in the pale body regions (Figure 2G; thicker arrows)
compared to the neurons lacking pale bodies (Figure 2G; asterisks).
T417 pElk in Neurodegeneration
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intense immunostaining for Elk-1 (Figure 2I) appears to be at a
later stage of inclusion development, in that it contains multiple
early Lewy bodies at its periphery (dashed ellipses, Figure 2H). In
addition to total Elk-1, T417
+ Elk-1 is also present in pale bodies.
In sum, these experiments show that T417
+ Elk-1 specifically
associates with inclusions characteristic of human Lewy body
disease tissue.
Figure 2. T417
+ Elk-1 co-localizes with Lewy Bodies and pale bodies in human Lewy Body Disease tissue. A classic Lewy body in a
neuromelanin-containing substantia nigra neuron (arrow in Panel A) also stains with Elk-1 (bluish-black, arrow in Panel B) and alpha-synuclein (red,
arrow in Panel C) in immediately adjacent sections (patient LB7; scale bars, 20 mm; original magnification, 4006). A SN neuron contains multiple T417
+
Elk-1 inclusions (bluish-black, arrows in Panel D). Following an acid removal procedure the section is overlaid with H&E. T417
+ Elk-1 inclusions exhibit
dark pink eosinophilic centers surrounded by lighter pink halos (patient LB6; scale bars, 20 mm; original magnification, 10006). A SN section contains
neurons with pale bodies (arrows in Panel F) and neurons that do not (asterisks in Panel F). The corresponding Elk-1immunoreactivity is shown for
these neurons (Panel G) (patient LB4, scale bars, 20 mm; original magnification, 4006). A higher magnification of a pale-body containing neuron
(arrow in Panel H) with its corresponding Elk-1immunoreactivity (arrow in Panel I) (scale bars, 20 mm; original magnification, 10006).
doi:10.1371/journal.pone.0009002.g002
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We tested whether a specific association exists between T417
+
Elk-1 and inclusions in another major neurodegenerative disease.
Alzheimer’s Disease is characterized by a number of neuropath-
ological lesions, including neuritic plaques, neurofibrillary tangles,
and neuropil threads. These lesions can be identified by AT8, an
antibody directed against hyperphosphorylated Tau. Figure 3A–D
contains representative images showing that T417
+ Elk-1 co-
localizes with inclusions identified by AT8 in human Alzheimer’s
disease brain. A neuritic plaque labeled with AT8 immunostains
intensely for T417
+ Elk-1 in an adjacent section (arrow, Figure 3A/
3B). In addition, a subset of neurons containing neurofibrillary
tangles labeled with AT8 (arrows, Figure 3C), also immunostains
intensely for T417
+ Elk-1 in an adjacent section (arrows,
Figure 3D). T417
+ Elk-1 immunoreactivity also identifies numer-
ous neuropil threads throughout the section (Figure 3D). This is
consistent with the pattern of AT8 staining in the neuropil of
Alzheimer’s disease brain (Figure 3C). Furthermore, Figure 3E–G
contains representative images demonstrating that T417
+ Elk-1
inclusions display classic plaque, tangle and thread morphologies
in human AD brain. The co-localization of T417
+ Elk-1 with AD
inclusions is found in each AD case listed in Table S1.
Immunostaining with antibodies against S383
+ Elk-1 and T368
+
Elk-1 do not demonstrate co-localization with AT8-labeled
inclusions (Figure S3 A–C). Age-matched control tissue shows
little inclusion pathology. Occasional neurons do exhibit signifi-
cant extranuclear T417
+ Elk-1 immunostaining (Figure S2 C/D,
Figure S2 E/F; thick arrows). In sum, these experiments show that
T417+ Elk-1 specifically associates with neuronal inclusions
characteristic of Alzheimer’s Disease.
In Alzheimer’s Disease, different areas of the hippocampus
display distinct regional pathologies in terms of the number and
distribution of inclusions [22,23]. We find that T417
+ Elk-1
immunoreactivity specifically mimics this regional pathology
(Figure 4). In the CA2 region of hippocampus, note the sparse
tangle population zone identified by both AT8 (Figure 4A,
Figure 3. T417
+ Elk-1 co-localizes with plaque and tangle inclusions in human Alzheimer’s Disease tissue. A parahippocampal neuritic
plaque identified by AT8 (arrow in Panel A) also contains T417
+ Elk-1 immunoreactivity (arrow in Panel B) (patient AD2; scale bars, 200 mm; original
magnification, 406). Neurofibrillary tangles identified by AT8 (arrows in Panel C) also contain T417
+ Elk-1 immunoreactivity (arrows in Panel D) (scale
bars, 20 mm; original magnification, 2006). T417
+ Elk-1 inclusions show neurofibrillary tangle morphology (arrow in Panel E), neuritic plaque
morphology (asterisk in Panel E), as well as dystrophic neurite morphology (neuropil in Panel E). (patient AD2; scale bar, 20 mm; original
magnification, 4006). A higher magnification of a T417
+ Elk-1 neurofibrillary tangle surrounded by multiple T417
+ Elk-1 dystrophic neurites (arrows in
Panel F) (scale bar, 20 mm; original magnification 10006). A higher magnification of a T417
+ Elk-1 plaque containing multiple T417
+ Elk-1 dystrophic
neurites (arrows in Panel G). (scale bar, 20 mm; original magnification, 10006).
doi:10.1371/journal.pone.0009002.g003
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+ Elk-1 (Figure 4B, asterisk). In addition, note
the high density of plaque and tangle staining in CA1 identified by
both AT8 and T417
+ Elk-1 staining (Figure 4C/4D). Robust
neuritic inclusion staining is observed throughout the section.
Finally, hippocampus from age-matched control tissue processed
for T417
+ Elk-1 does not show advanced CA1 pathology or a
sparse tangle zone in CA2 (Figure S2C).
Elk-1 and Huntington’s Disease
Finally, we assessed whether T417
+ Elk-1 could associate with
inclusions present in human Huntington’s Disease tissue.
Huntington’s Disease is characterized by intraneuronal aggre-
gates of polyglutamine-containing Huntingtin protein. These
aggregates are found within diverse brain regions in both nuclear
and extranuclear compartments [24]. Ubiquitin is found within
these inclusions and is commonly used as a protein marker.
Figure 5A–H contains images showing that T417
+ Elk-1 co-
localizes with Ubiquitin
+ inclusions in human Huntington’s
Disease tissue. Ubiquitin
+ immunoreactivity identifies spherical
inclusions within HD striatum (all arrows, Figure 5A). A subset of
Ubiquitin
+ inclusions co-localizes with T417
+ Elk-1 (yellow
arrows, Figure 5A/5B). In addition, a subset of T417
+ Elk-1
inclusions does not contain Ubiquitin
+ immunoreactivity (red
arrows, Figure 5B). Higher magnification images demonstrate the
variance in size of the inclusions (Figure 5C–H). Overall, a
fraction of Ubiquitin
+ inclusions contains T417
+ Elk-1 and vice
versa. Multiple examples of colocalization could be seen across
the striatum from the HD cases listed in Table S1. Here, the
degree of co-localization can vary depending on both detection
and disease parameters [25].
Discussion
The transcription factor Elk-1 resides in both nuclear and
extranuclear neuronal compartments. Previously, we have shown
that extranuclear Elk-1 functions in regulating neuronal viability.
In this study, we identify the phosphosite T417 as being essential
for Elk-1 mediated neuronal death. Furthermore, we document
the co-localization of extranuclear T417
+ Elk-1 with multiple
types of neuronal inclusions from three major neurodegen-
erative diseases. These findings raise the interesting possibility
that Elk-1 impacts neuronal viability within the context of
neurodegeneration.
The finding that Elk-1 mediated neuronal death is dependent
on a specific phosphosite suggests that posttranslational modifica-
tions can confer novel functional properties upon Elk-1 protein. In
our in vitro model, the de novo synthesis of Elk-1 within a single
dendrite leads to a local enrichment of Elk-1 protein within this
subcellular compartment. This local enrichment may drive its
association with a T417
+ Elk-1 kinase that is also present in this
extranuclear compartment. Similarly, the neurodegenerative
microenvironment may lead to the local enrichment of extranu-
clear Elk-1 especially around the areas of inclusion formation.
Here, this local enrichment could occur through the de novo
synthesis of Elk-1 protein or through its subcellular movement. In
addition, the neurodegenerative microenvironment may locally
stimulate T417
+ Elk-1 kinase activity.
The co-localization of T417
+ Elk-1 with multiple neuronal
inclusions suggests a common mechanism of pathogenesis and
neuronal loss among distinct neurodegenerative diseases. The
inclusions may sequester T417
+ Elk-1 as it is being enriched,
Figure 4. T417
+ Elk-1 immunoreactivity mimics hippocampal regional pathology in human AD tissue. Serially adjacent sections
containing AD hippocampus demonstrating the expression pattern of AT8 (Panels A,C) and T417
+ Elk-1 (Panels B,D). Note the sparse tangle
population in CA2 is identified by both AT8 (asterisk in Panel A) and T417
+ Elk-1 (asterisk in Panel B) (patient AD2; scale bars, 200 mm; original
magnification 406). Abundant inclusion pathology in CA1 is identified by both AT8 (Panel C) and T417
+ Elk-1 (Panel D). (scale bars, 200 mm; original
magnification, 406).
doi:10.1371/journal.pone.0009002.g004
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association with other components in the cell death pathway.
However, the enrichment of this neurotoxic protein may exceed
the subcellular capacity of containment resulting in the liberation
of active molecules of T417
+ Elk-1. Alternatively, the inclusions
could serve as subcellular pathogenic sites that actually enhance
the local enrichment and activation of T417
+ Elk-1. T417
+ Elk-1
molecules could then dissociate from these sites and initiate
neuronal death (Figure S4). The fact that a subset of inclusions
from Parkinson’s Disease and Huntington’s Disease show
colocalization with T417
+ Elk-1 likely reflect both disease and
detection processes. Not all the neurons containing inclusion
pathology likely undergo cell death or show Elk-1 enrichment at a
given time. Alternatively, because limited and localized levels of
Elk-1 enrichment can induce changes in cell viability [8], its
possible that extranuclear Elk-1 may be biologically active even
where signal can not be readily detected.
The linkage between Elk-1 and neurodegeneration raises an
interesting set of issues regarding its potential as a therapeutic
target[26,27]. Its association with several types of inclusions
Figure 5. T417
+ Elk-1 co-localizes with Ubiquitin
+ inclusions in human HD tissue. Striatal inclusions identified by Ubiquitin
+
immunoreactivity (yellow arrows in Panel A) also contain T417
+ Elk-1 immunoreactivity (yellow arrows in Panel B) (patient HD7; scale bars, 50 mm).
Green arrows identify inclusions only containing ubiquitin. Red arrows identify inclusions only containing T417
+ Elk-1. Higher magnification images of
insets (Panels C–H) (scale bars, 20 mm).
doi:10.1371/journal.pone.0009002.g005
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pathogenesis shared across a spectrum of neurodegenerative
disease. Its ability to initiate regionalized neuronal death could
be triggered by neurodegenerative processes believed to start
within synaptic compartments. Also, that a specific phosphoform
of Elk-1 both associates with inclusions and regulates neuronal
viability suggests a molecular link from pathogenesis to cell loss
dependent upon an activated form of Elk-1. Furthermore, the
staining of T417
+ Elk-1 confirms its enrichment in extranuclear
compartments where it functions to regulate neuronal viability.
Finally, in Alzheimer’s Disease, where the staining is more intense
then the canonical AT8 staining, T417
+ Elk-1 may serve as an
early biomarker for neurodegenerative processes. Currently, there
are no known Elk-1 single-nucleotide poIymorphisms associated
with neurodegenerative disease. However, it’s likely that the role of
Elk-1 in regulating neuronal viability is part of a common cellular
response to regional cellular insults. In this case, SNPs may not be
expected. Alternatively, genetic variants of multiple proteins
involved in the Elk-1 cell death pathway could share an association
with neurodegenerative disease. Accessing the absence of Elk-1 on
the progression of neurodegeneration will be critical in establishing
its importance in these diseases. In addition, efforts to identify
components of the cell death pathway, including T417
+ Elk-1
kinase(s) will be essential in translating these studies into novel
treatment strategies.
Materials and Methods
Neuronal Cell Culture
Primary neurons from E18 rat hippocampi were plated in
MEM (Gibco 11095-080) supplemented with 0.6% wt/vol
glucose, 1 mM sodium pyruvate, and B27 (Invitrogen). The cells
were placed on spiegelglas coverslips (Carolina Biological) coated
with 80 mg/ml Poly-D-Lysine MW 70–150,000 (Sigma) in borate
buffer and 1 mg/ml Laminin (BD Bioscience) in borate buffer.
Site-Directed Mutagenesis
Single amino acid substitutions were placed at sites of post-
translational modification using the QuikChange Site-Directed
Mutagenesis kit (Stratagene). A pcDNA3.1A plasmid vector
(Invitrogen) containing Elk-1 cDNA (derived from IMAGE #
BC054474) was amplified using a high-fidelity DNA polymerase
and PCR primers with specific single codon mutations. For the
S383A mutant, the following primers were utilized: ccatttctggag-
cactctggcgccaattgcaccccgtagt and actacggggtgcaattggcgccagagtgc-
tccagaaatgg. For the T417A mutant, the following primers were
utilized: atcagtgtggatggcctctcggcgcccgtggtgctctccc and gggagag-
caccacgggcgccgagaggccatccacactgat. Following PCR, DNA se-
quencing was used to verify that site-specific mutations had been
created.
Phototransfection
The capped Elk-1 mRNAs were synthesized (Ambion mMes-
sage mMachine) and verified via a Bioanalyzer (Agilient). Prior to
phototransfection, the concentration of mRNA placed in the
cellular bath was 40–80 ug/ml. Phototransfection was performed
on a multi-photon upright microscope (Zeiss 510 NLO) with a
Ti:Sapphire laser (Mai-Tai DeepSee, Spectra Physics). Based on
the transmitted light gradient contrast image or weak cellular
autofluorescence of 2–3 wk IV primary hippocampal neurons, we
selected three distinct regions of interest (262 pixel each) over a
dendrite for phototransfection. Immediately following bath
application of mRNA, we then used the Ti:Sapphire laser to
make transient poration sites by delivering pre-chirped pulses
(100 fs pulses, 80 MHz repetition rate) at 35 mW power (at the
back aperture of the lens) for 25 msec per pixel. The pulses were
delivered sequentially over the pixels within the regions of interest.
After phototransfection, cell viability was assessed up to 6 hours
later by determining the presence of clear cellular morphological
changes such as somatic swelling, dendritic fragmentation and
nuclear compaction.
Patient Information and Tissue Inclusion
Tissue used in this study was made possible by postmortem
organ donation of participating patients to the University of
Rochester Medical Center Neuropathology Unit. The program is
rigorously administered by the Autopsy Unit of the University of
Rochester Medical Center Pathology Department. HIPPA policy
is in effect for the patients and their families and, as such, the cases
reported here have been coded to prevent patient identification.
The University of Rochester Neuropathology Unit obtained
permission from the Institutional Review Board at the University
of Rochester Medical Center for this study.
Following an extensive screening procedure, cases were chosen
retrospectively based on their final postmortem diagnoses. Cases
designated ‘‘Lewy body disease’’ or ‘‘Alzheimer’s disease’’ were
considered only if they showed disease-specific pathology. Cases
with severe pathology were excluded due to the deficiency of
neurons to assess co-localization. Age-matched controls lacking
pathological changes in substantia nigra, hippocampus, and basal
ganglia were also included for comparison (see Table S1 for case
descriptions).
Tissue Processing
At the time of autopsy, brain regions were carefully dissected
and a 3 mm slice from the brain region of interest was placed in a
tissue cassette. Cassettes were placed in formalin fixative for three
days, and subsequently infiltrated with paraffin. Serial sections
were cut and mounted in a similar orientation on serial Frosted
Plus slides to enable identification of inclusion-containing cells and
to visualize immunohistochemical results.
The data reported here are from 7 um serial section series
undertaken for each of the diseases listed. All serial sets began with
the first slide processed for hematoxylin and eosin using standard
University of Rochester Neuropathology processing. Additional
slides within the series also were processed for H&E to allow for
neurons to be matched across sections. Specific neurons were
located within and across adjacent sections using blood vessel
morphology and tissue architecture.
Immunohistochemistry: Parkinson’s and Alzheimer’s
Sections
Paraffin sections were placed in fresh xylene, passed through a
graded percentage of alcohol and subsequently placed in 0.15 M
phosphate buffer, pH 7.4. Sections were then placed in slide
mailers and processed in 3% hydrogen peroxide followed by a
phosphate buffer wash. Antigen retrieval was necessary to observe
immunohistochemical staining for Elk-1. Antigen retrieval was
accomplished by placing the sections in 0.01 M citrate buffer at
100uC for 20 minutes in a microwave oven. Slides were cooled for
20 minutes, washed and placed in 0.15 M phosphate buffer,
pH 7.4. Blocking was accomplished using a high block buffer
containing 10% BSA, 10% goat serum, 0.1% Triton X-100 in
0.15 M phosphate buffer. 8 ml avidin (Vector labs Avidin/Biotin
Blocking System) was added to a total of 50 ml of block buffer.
Slides were blocked overnight at 4uC and then placed in primary
antibody. Primary antibody dilutions are listed below. Multiple
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staining. The final buffer used for all primary antibodies contained
5% BSA, 5% serum (from the species of the secondary antibody)
and 0.1% Triton X-100 in 0.15 M phosphate buffer (‘‘5/5’’ block
buffer). 8 ml biotin (Vector Labs) was added to every 50 ml of ‘‘5/
5’’ block buffer. Slides were incubated in slide mailers containing
the appropriate primary antibody for 48 hours at 4uC with
constant rotation. Slides containing age-matched control tissue
were placed in the same slide mailers as the diseased state tissue.
For each disease, slides were processed for each antibody
simultaneously such that only the primary and secondary reagents
were different - all other reagents and procedures were identical.
The following day, slides were removed from the primary
antibody solution and washed in ‘‘5/5’’ block buffer. Subsequent-
ly, they were incubated in the appropriate secondary antibody in
‘‘5/5’’ block buffer with constant rotation for one hour at room
temperature and then washed in 0.15 M phosphate buffer,
pH 7.4. Avidin incubation was accomplished using the avidin/
biotinylated horseradish peroxidase system (ABC Elite System)
from Vector Labs. ABC was applied for one hour at room
temperature with constant rotation. Slides were then washed in
phosphate buffer followed by three Tris-base buffer washes. The
chromagens used for detection were either diaminobenzidine
(DAB) with nickel enhancement (Vector Labs DAB System) or 3-
amino-9-ethylcarbazole (AEC). Intensity of the reaction product
was observed using a wet microscope and stopped at the
appropriate time in water. Slides containing DAB reaction product
were processed through a graded series of alcohols and mounted
using Cytoseal low viscosity mounting media (VWR). Slides
containing AEC were mounted in the aqueous mounting media,
Mowiol.
The Elk-1 primary antibodies utilized include Elk-1 (1:500, Cell
Signaling, #9182, rabbit polyclonal), S383
+Elk-1 (1:250, Cell
Signaling, #9186, mouse monoclonal), T417
+Elk-1 (1:500, custom
made by JE lab, rabbit polyclonal) and T368
+ Elk-1 (1:1000,
custom made by JE lab, rabbit polyclonal). The inclusion-specific
antibodies utilized include AT8 (1:1000, Pierce, 24 hour incuba-
tion at 4C, mouse) for neurofibrillary tangles and Alpha-synuclein
(1:7500, Zymed, mouse) for Lewy bodies. The secondary
antibodies utilized include biotinylated goat anti-rabbit (1:1000,
Vector Labs) and biotinylated goat anti-mouse (1:1000, Vector
Labs). Peptide competition experiments were performed for each
antibody (Figure S5, Figure S6).
Immunohistochemistry: Huntington’s Sections
Paraffin sections were placed in fresh xylene, passed through a
graded percentage of alcohol and subsequently placed in 0.15 M
phosphate buffer, pH 7.4. Following a series of TBS washes,
antigen retrieval was performed by placing the slides in 1% SDS in
TBS at 37uC for 20 minutes. The slides were then extensively
rinsed in a large volume of TBS at RT. Blocking was
accomplished using a buffer containing 3% BSA, 10% goat
serum, 2% Triton-X100 in TBS at 37uC for 75 minutes. Slides
were then incubated with the appropriate primary antibody
(T417
+ Elk-1 (1:50, custom made by JE lab, rabbit polyclonal),
anti-Ubiquitin (1:100, Chemicon, mouse monoclonal)) in a buffer
containing 3% BSA in 1% TBST at 37uC for 2 hrs, then at 4uC
overnight, and finally 37uC for 2 hrs. After rinses in 0.1% TBST
and rinses in borate buffer, the slides were re-blocked in 2% BSA
in borate buffer at RT for 15 minutes. Slides were incubated with
Qdot secondary antibodies (Qdot 525 goat anti-rabbit IgG
(50 nM, Invitrogen), Qdot 655 goat anti-mouse IgG (20 nM,
Invitrogen)) at RT for 3 hrs and then 37uC for 1 hr. Following a
series of washes in borate buffer, the slides were mounted in borate
buffer for immediate imaging. Slides containing age-matched
control tissue were placed in the same slide mailers as the diseased
state tissue.
Imaging
Following immunohistochemistry, sections from Parkinson’s
and Alzheimer’s disease were analyzed using a MicroFire Camera
driven by PictureFrame software on an Olympus Vanox AH-2
microscope through the University of Rochester Medical Center
Confocal and Conventional Microscopy Core. Original raw data
images are archived. Following Microscopy Society of America
recommendations, processing of images consisted of only changes
in contrast and brightness of the entire original image through
PictureFrame software. Range of image processing for contrast
and brightness to the entire image were between 220 and +25.
Gamma was changed only for the entire image of Figure 1c to a
value of 1.12. Images in Figure 2a–2c were cropped to aid in
comparison across adjacent sections.
Following immunohistochemistry, sections from Huntington’s
disease were imaged for Qdot fluorescence using a Zeiss 510 Meta
confocal microscope. Excitation at 458 nm was used to elicit Qdot
emission. Qdot emission from both the Qdot 525 goat anti-rabbit
IgG and the Qdot 655 goat anti-mouse IgG could be segregated
across two channels with distinct bandwidths (Chs1: 511.60–
533 nm; Chs2: 640–660 nm). To minimize tissue autofluores-
cence, a photobleaching protocol was implemented. Here, using a
defined set of parameters, a region-of-interest was imaged with
high-transmission, multi-wavelength excitation. This resulted in a
significant reduction in tissue autofluorescence across both
channels without a reduction in Qdot emission intensity.
Supporting Information
Methods S1
Found at: doi:10.1371/journal.pone.0009002.s001 (0.03 MB
DOC)
Table S1 1 Includes a spectrum of disease from preclinical
presentation of Lewy bodies, Parkinson’s variant of Lewy body
disease, Lewy body disease with neocortical involvement. 2
Standard neuropathology procedures used for severity grading. 3
Vonsattel grading system. 4 Age-matched controls were deemed
free of major disease in substantia nigra, hippocampus, entorhinal
cortex, and basal ganglia. * Age of onset was determined by year
symptoms were recognized as being abnormal and brought to the
attention of a clinician, preclinical indicates that obvious disease
symptoms were not present or reported.ˆ Post-mortem interval.
Found at: doi:10.1371/journal.pone.0009002.s002 (0.08 MB
DOC)
Table S2 Disease severity grade for Lewy Body Disease cases.
Rating code: +/2 = little neuronal loss and presence of only a
few pale and Lewy bodies. +1= focal neuronal loss and gliosis.
+2= multiple areas of neuronal loss and gliosis. +3= severe
neuronal loss (cases with this severity were not included in this
study due to the lack of inclusions present). * number of neurons
containing Pale bodies or Lewy bodies was assessed by examining
a single, diagnostic H and E stained substantia nigra section from
each case.
Found at: doi:10.1371/journal.pone.0009002.s003 (0.03 MB
DOC)
Figure S1 S383+ Elk-1 and T368+ Elk-1 do not co-localize with
Lewy body inclusions in human PD tissue. Sections containing
substantia nigra were processed for S383+ Elk-1 (A) and T368+
Elk-1 (B). Hashed circles identify Lewy body inclusions. (scale bars,
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S383+ Elk-1or T368+ Elk-1 immunoreactivity is observed within
the inclusions.
Found at: doi:10.1371/journal.pone.0009002.s004 (2.28 MB TIF)
Figure S2 T417+ Elk-1 localizes to both nuclear and extranu-
clear compartments within diverse regions of control human brain
tissue. Sections from patient CON2 containing substantia nigra (A,
100x), hippocampus (C, 40x) and entorhinal cortex (E, 40x) were
processed for T417+ Elk-1 (scale bars, 200 mm). Higher magni-
fications of insets are shown for these respective regions (B,
20 mm/4006;D ,2 0mm/2006; F, 200 mm/1006). Thin arrows
highlight neurons with nuclear T417+ Elk-1 immunoreactivity,
thick arrows highlight neurons with extranuclear T417+ Elk-1
immunoreactivity.
Found at: doi:10.1371/journal.pone.0009002.s005 (8.21 MB TIF)
Figure S3 S383+ Elk-1 and T368+ Elk-1 do not co-localize with
plaque and tangle inclusions in human AD tissue. Serially adjacent
sections containing CA1 hippocampus were processed for AT8
(A), S383+ Elk-1 (B) and T368+ Elk-1 (C) (scale bars, 200 mm;
original magnification, 406). The area between the two blood
vessels (BV) identifies numerous AT8 immunoreactive cells.
Minimal S383+ Elk-1or T368+ Elk-1 immunoreactivity is
observed within the neurons in this area.
Found at: doi:10.1371/journal.pone.0009002.s006 (3.74 MB TIF)
Figure S4 Proposed mechanisms linking T417+ Elk-1 inclusions
with neuronal loss. Protein synthesis of Elk-1 and its phosphor-
ylation at T417 within extracellular compartments creates a toxic
protein capable of influencing neuronal viability (A) (Elk-1, orange
circles; ribosomes, green circles; T417 Elk-1 kinase, blue ovals).
Neurodegenerative inclusions may represent sites capable of
containing toxic proteins such as T417+ Elk-1 (B1) (inclusion,
large yellow circle). Alternatively, the inclusions may serve as sites
allowing for further enrichment or activation of T417+ Elk-1 (B2).
When enrichment mechanisms supercede inclusion containment
mechanisms (C1) neuronal death is initiated (D) (mitochondria,
ovals labeled ‘‘mito’’). Alternatively, T417+ Elk-1 molecules break
away from their sites of activation (C2) initiating neuronal death
(D).
Found at: doi:10.1371/journal.pone.0009002.s007 (0.44 MB TIF)
Figure S5 Signal from Elk-1 antibody is blocked by a specific
peptide. Serially adjacent sections containing AD hippocampus
were processed with Elk-1 primary (A), without primary antibody
(B), and an Elk-1 primary: Elk-1 peptide mixture (C) (scale bars,
200 mm; original magnification, 406).
Found at: doi:10.1371/journal.pone.0009002.s008 (3.18 MB TIF)
Figure S6 Signal from pElk-1 antibodies are blocked by specific
phospho-peptides. Western blot analysis identifying T417+ Elk-1
and T368+ Elk-1 as 62kD bands in C57BL/6 lysate. The lysate
was probed with a pElk-1 antibody (2nd lanes), pElk-1 antibody:
peptide (pep) mixture (4th lanes) and a pElk-1 antibody:
phosphopeptide (P04pep) mixture (6th lanes). A 50kD loading
control was placed in the alternate lanes.
Found at: doi:10.1371/journal.pone.0009002.s009 (2.24 MB TIF)
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